SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Zeev's Turnips - No Politics -- Ignore unavailable to you. Want to Upgrade?

To: Casaubon who wrote (34437)2/27/2002 6:25:59 PM
From: lh56  Read Replies (1) | Respond to of 99280
 
re: btk. (excerpted from b.c story on seasonal sector strengths)

"The biotech sector is not only ending its best stretch (Dec through Feb for an avg gain of 25.8%) but March also marks the start (and fortunately the end) of its worst period for an avg loss of 8.4%. The components include: AFFX, AMGN, BGEN, CRA, CEPH, CHIR, DNA, GENZ, GILD, HGSI, IDPH, IMNX, IVGN, MEDI, MLNM, PDLI, VRTX."

don't know if it'll be true this march, but, i'll certainly have AFFX in my sights.

-larry



To: Casaubon who wrote (34437)2/27/2002 7:18:01 PM
From: seminole  Read Replies (1) | Respond to of 99280
 
The smaller the bio company, the more important are the various market sources for money.
IPO and Venture Cap money is easier to find with good markets.
Small bio companies need funding so they need good markets and the funding it brings.
This may explain the lag you have observed.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News